成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook
Chinese english Japan Germany
ChemicalBook > 製品カタログ > 生物化學(xué)工學(xué) > インヒビター > タンパク質(zhì)チロシンキナーゼ > コビメチニブ

コビメチニブ

コビメチニブ price.
  • ¥3825400 - ¥3825400
  • 化學(xué)名: コビメチニブ
  • 英語(yǔ)名: XL518
  • 別名:コビメチニブ;1-{3,4-ジフルオロ-2-[(2-フルオロ-4-ヨードフェニル)アミノ]ベンゾイル}-3-[(2S)-ピペリジン-2-イル]アゼチジン-3-オール;[3,4-ジフルオロ-2-(2-フルオロ-4-ヨードフェニルアミノ)フェニル][3β-ヒドロキシ-3-[(2S)-2-ピペリジニル]-1-アゼチジニル]メタノン
  • CAS番號(hào): 934660-93-2
  • 分子式: C21H21F3IN3O2
  • 分子量: 531.31
  • EINECS:
  • MDL Number:MFCD22124461
1物価
選択條件:
ブランド
  • 富士フイルム和光純薬株式會(huì)社(wako)
パッケージ
  • 1g
  • 生産者富士フイルム和光純薬株式會(huì)社(wako)
  • 製品番號(hào)W01MAS125087
  • 製品説明
  • 英語(yǔ)製品説明Cobimetinib
  • 包裝単位1g
  • 価格¥3825400
  • 更新しました2024-03-01
  • 購(gòu)入
生産者 製品番號(hào) 製品説明 包裝単位 価格 更新時(shí)間 購(gòu)入
富士フイルム和光純薬株式會(huì)社(wako) W01MAS125087
Cobimetinib
1g ¥3825400 2024-03-01 購(gòu)入

プロパティ

融點(diǎn)  :165 - 166°C
沸點(diǎn)  :565.9±50.0 °C(Predicted)
比重(密度)  :1.706
貯蔵溫度  :Refrigerator
溶解性 :Chloroform (Slightly), DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
外見(jiàn)  :Solid
酸解離定數(shù)(Pka) :13.13±0.20(Predicted)
色 :Off-White

安全情報(bào)

絵表示(GHS): GHS hazard pictograms
注意喚起語(yǔ): Warning
危険有害性情報(bào):
コード 危険有害性情報(bào) 危険有害性クラス 區(qū)分 注意喚起語(yǔ) シンボル P コード
注意書き:

説明

Cobimetinib, codeveloped by Genentech and Exelixis, was approved in August 2015 in Switzerland and November 2015 in the U.S. and Europe for the treatment of unresectable or metastatic BRAFV600 mutationpositive melanoma when used in combination with vemurafenib. Cobimetinib is a potent, highly selective reversible inhibitor of mitogen-activated protein kinases (MEK) 1 and 2,120 which serves to inhibit phosphorylation of ERK1/2,121 disrupting the MAPK pathway which is responsible for cell proliferation, cell survival, and migration.122 Combination of cobimetinib with vemurafenib, an important BRAF inhibitor,123 enables targeting of multiple points on the MAPK pathway, leading to overall enhanced tumor cell apoptosis and response as compared to stand-alone treatment with vemurafenib.124 Specifically, in a representative trial of previously untreated patients with BRAFV600 mutation-positive, unresectable, stage IIIc or IV melanoma, combination of these two therapies led to a significantly improved progression-free survival and overall response rate versus patients treated only with vemurafenib.

関連商品価格